Age-related macular degeneration, a potentially blinding disease,is now epidemic in the developed world. Roughly one in threepeople will be affected to some degree by the age of 75 years.1Medicine's tremendous successes in the battles against cancer,diabetes, hypertension, heart disease, and other common killershave raised the average life expectancy in many countries tomore than 75 years and in so doing have inadvertently delivereda new scourge to mankind.
In this issue of the Journal, de Jong2 discusses age-relatedmacular degeneration as a complex disorder that begins decadesbefore a patient becomes symptomatic, a molecular derangement. . . [Full Text of this Article]
Source Information
From the Carver Family Center for Macular Degeneration, Howard Hughes Medical Institute, University of Iowa Carver College of Medicine, Iowa City.
This article has been cited by other articles:
Lee, T.-Y., Tjin Tham Sjin, R. M., Movahedi, S., Ahmed, B., Pravda, E. A., Lo, K.-M., Gillies, S. D., Folkman, J., Javaherian, K.
(2008). Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy. Clin. Cancer Res.
14: 1487-1493
[Abstract][Full Text]
McGimpsey, S J, Gillies, M C
(2008). Treatment of macular degeneration - controversy and hope. Br. J. Ophthalmol.
92: 436-437
[Full Text]
D'Amore, P. A.
(2007). Vascular Endothelial Cell Growth Factor-A: Not Just for Endothelial Cells Anymore. Am. J. Pathol.
171: 14-18
[Full Text]
Chakravarthy, U.
(2006). Age related macular degeneration.. BMJ
333: 869-870
[Full Text]
(2006). New Treatment for Age-Related Macular Degeneration. JWatch General
2006: 1-1
[Full Text]